Markets:

Overview

News

Currencies

International

Treasuries

Johnson & Johnson (NY:JNJ)

243.45 -1.10 (-0.45%)

Official Closing Price Updated: 7:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Johnson & Johnson

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

99 100 Next >

Want to Generate at Least $1,000 in Passive Income Per Year? Invest $26,000 in This Dividend King Stock. ↗

July 15, 2025

Via The Motley Fool

Topics Retirement

Should You Buy Johnson & Johnson Stock Before July 16th? ↗

July 15, 2025

Via The Motley Fool

Topics Government World Trade

These 3 Undervalued Stocks Could Surge as Value Rotation Nears ↗

July 14, 2025

A rotation back into value stocks may be imminent in today's market, giving investors a chance to expose themselves into a catch up play.

Via MarketBeat

Topics ETFs Economy

Andrew Hill Dumps 38,000 Johnson & Johnson Shares in Q2 2025 Exit ↗

July 14, 2025

Via The Motley Fool

Topics Regulatory Compliance

P/E Ratio Insights for Johnson & Johnson ↗

July 09, 2025

Via Benzinga

Kenvue CEO Thibaut Mongon Steps Down, Director Kirk Perry To Take On Interim CEO Role ↗

July 14, 2025

Perry has previously worked with Circana, Google, and was with Procter and Gamble for 23 years.

Via Stocktwits

Topics Government Stocks

This Stock Has Increased 4,720%: Here's Why It's Still a Buy ↗

July 13, 2025

Via The Motley Fool

5 of the Best Stocks to Buy in July ↗

July 11, 2025

These stocks are ready to pop higher.

Via The Motley Fool

Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies ↗

July 11, 2025

Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.

Via Benzinga

Topics Government World Trade

The Best High Yield Medical Device Stock to Invest $1,000 in Right Now ↗

July 11, 2025

Via The Motley Fool

What Is Considered a Good Dividend Stock? 3 Healthcare Stocks That Fit the Bill ↗

July 11, 2025

A steady dose of quality companies will keep your portfolio growing big and strong.

Via The Motley Fool

Topics Intellectual Property

Johnson & Johnson Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts ↗

July 11, 2025

Via Benzinga

2 Dividend Stocks to Double Up on Right Now ↗

July 11, 2025

Via The Motley Fool

Forecasting The Future: 8 Analyst Projections For Johnson & Johnson ↗

July 10, 2025

Via Benzinga

Option Wheel Strategy: How to Earn Monthly Income Trading Options

July 10, 2025

The search for consistent, predictable income is a constant for investors in both bull and bear markets. While traditional dividend stocks and bonds are reliable tools, a lesser-known but increasingly...

Via MarketMinute

Topics Bonds Retirement

Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity ↗

July 10, 2025

Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal.

Via Investor's Business Daily

Topics Intellectual Property

Johnson & Johnson's Outlook Clouded By $2 Billion Headwind ↗

July 09, 2025

Johnson & Johnson's 2025 outlook sees slight EPS and revenue upgrades, while headwinds from biosimilars and tariffs are expected to weigh on performance.

Via Benzinga

Topics World Trade

Johnson & Johnson (NYSE:JNJ) – A Reliable Dividend Stock Worth Considering ↗

July 09, 2025

Johnson & Johnson (NYSE:JNJ) offers a reliable 3.33% dividend yield with strong profitability and financial health, making it a solid pick for dividend investors.

Via Chartmill

Trump Threatens 200% Tariffs On Drug Imports, Says Big Pharma Will Get Some Time 'To Get Their Act Together' ↗

July 08, 2025

Pharmaceutical investors are being cautious, with concerns over potential supply disruptions, cost pressures, and uncertainty regarding policy implementation.

Via Stocktwits

Topics ETFs Economy Government

Johnson & Johnson Submits Supplemental Drug Application To FDA For Schizophrenia Drug Caplyta ↗

July 08, 2025

J&J gained access to Caplyta by the acquisition of Intra-Cellular Therapies, Inc., which was completed in April.

Via Stocktwits

Topics Government

FDA Issues Early Alert For Johnson & Johnson's Abiomed Heart Pump Controllers ↗

July 07, 2025

FDA issued an Early Alert for Abiomed's Automated Impella Controllers due to potential safety concerns following reports of 3 deaths.

Via Benzinga

Should You Forget Johnson & Johnson and Buy This Magnificent High-Yield Dividend Stock Instead? ↗

July 07, 2025

Via The Motley Fool

Trump's 'Big, Beautiful Bill' Hands $5 Billion Win To Big Pharma: Report ↗

July 04, 2025

Trump's $3.3 trillion domestic agenda bill, passed by the House on Thursday, includes a significant victory for pharmaceutical companies .

Via Benzinga

Topics Government

10 Health Care Stocks With Whale Alerts In Today's Session ↗

July 02, 2025

Via Benzinga

Dogs Of The Dow: How You Can Get Dividend Stocks With Yields Up To 6.3% ↗

July 01, 2025

The Dow Jones Industrial Average stocks average a 2% dividend yield through the first six months of 2025. Here are the top yields.

Via Benzinga

Topics Stocks

Johnson & Johnson's Drug Discount Plan Gets Thrown Out In Court ↗

July 01, 2025

A federal court denied Johnson & Johnson's motion to implement a 340B drug rebate model, siding with HHS and hospitals who argued it violated program intent.

Via Benzinga

July 01, 2025

Via The Motley Fool

Topics Artificial Intelligence ETFs Stocks

FDA Flags Weight Loss Risk In ADHD Meds For Kids — J&J, Novartis Escape New Warning ↗

June 30, 2025

The updated label applies to extended-release stimulants prescribed off-label to children under six, following data showing higher drug exposure and side effect rates in that age group.

Via Stocktwits

FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers ↗

June 30, 2025

FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment.

Via Benzinga

Johnson & Johnson Is Great. Here's Why You Shouldn't Buy It. ↗

June 27, 2025

Via The Motley Fool

Topics Lawsuit Supply Chain

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Johnson & Johnson (NY:JNJ)

Headline News about Johnson & Johnson

Starting at $3.75/week.

Subscribe Today